Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.

British journal of haematology - 1 Jul 2010

Dawson Mark A, Curry Jayne E, Barber Kelly, Beer Philip A, Graham Brent, Lyons John F, Richardson Caroline J, Scott Mike A, Smyth Tomoko, Squires Matthew S, Thompson Neil T, Green Anthony R, Wallis Nicola G

Abstract excerpt

Constitutive activation of Janus kinase (Jak) 2 is the most prevalent pathogenic event observed in the myeloproliferative disorders (MPD), suggesting that inhibitors of Jak2 may prove valuable in their management. Inhibition of the Aurora kinases has also proven to be an effective therapeutic strategy in a number of haematological malignancies. AT9283 is a multi-targeted kinase inhibitor with potent activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase B
Share to Aurora Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Drug Evaluation, Preclinical

Share to Erythroid Precursor Cells

Share to Leukemia, Experimental

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 20507304
DOI: 10.1111/j.1365-2141.2010.08175.x

Genes

JAK2
ETV6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.PMID 20507304Read ↗

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.Semantic proximity Read ↗

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Semantic proximity Read ↗

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesSemantic proximity Read ↗

The potential role of Aurora kinase inhibitors in haematological malignanciesSemantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.Semantic proximity Read ↗

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemiaSemantic proximity Read ↗

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Semantic proximity Read ↗

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cellsSemantic proximity Read ↗

Aurora kinases and their inhibitors: more than one target and one drug.Semantic proximity Read ↗

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.Semantic proximity Read ↗

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase InhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.